within Pharmacolibrary.Drugs.ATC.R;

model R07AA01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 67.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R07AA01</td></tr><td>route:</td><td>intratracheal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Colfosceril palmitate is a synthetic pulmonary surfactant used primarily in the prevention and treatment of neonatal respiratory distress syndrome (RDS) in premature infants. It acts by reducing surface tension in the lungs, thus improving lung compliance and gas exchange. It was marketed under the trade name Exosurf but is no longer widely used or approved today, having been replaced by more effective animal-derived surfactant preparations.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data are available; estimates are based on the nature of the drug as an exogenous surfactant administered intratracheally to premature neonates.</p><h4>References</h4><ol><li><p>DeAngelis, RL, &amp; Findlay, JW (1993). Metabolism of synthetic surfactants. <i>Clinics in perinatology</i> 20(4) 697–710. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8131363/&quot;>https://pubmed.ncbi.nlm.nih.gov/8131363</a></p></li><li><p>N&#x27;Guessan, A, et al., &amp; Tsapis, N (2018). Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 113 185–192. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2017.09.013&quot;>10.1016/j.ejps.2017.09.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28890202/&quot;>https://pubmed.ncbi.nlm.nih.gov/28890202</a></p></li><li><p>Gupta, V, et al., &amp; Ahsan, F (2013). Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 167(2) 189–199. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2013.01.011&quot;>10.1016/j.jconrel.2013.01.011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23353807/&quot;>https://pubmed.ncbi.nlm.nih.gov/23353807</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R07AA01;
